Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study~* Written informed consent will have been obtained from the subjects before the blood sampling visit of each year.

- Gender: ALL
- Minimum Age: 29 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Havrix Group (Type: EXPERIMENTAL): Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).